SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Bavarian Nordic A/S BVNKF OTC

Other OTC • Healthcare • Biotechnology • DK • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Bavarian Nordic A/S (BVNKF) is a Biotechnology company in the Healthcare sector, currently trading at $30.73. It has a SharesGrow Score of 83/100, indicating a strong investment profile with 4 out of 7 criteria passed.

Financials: revenue is $6.2B, +37.6%/yr average growth. Net income is $1.4B, growing at +176.8%/yr. Net profit margin is 22.3% (strong). Gross margin is 47.4% (-6.6 pp trend).

Balance sheet: total debt is $131M against $12.8B equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 4.22 (strong liquidity). Debt-to-assets is 0.9%. Total assets: $14.9B.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 100/100 (Pass), Past 75/100 (Partial), Health 100/100 (Pass), Moat 52/100 (Partial), Future ?/100 (Fail), Income 85/100 (Pass).

BVNKF SharesGrow Score Overview

85/100

SharesGrow Score

Strong investment profile

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 100/100

Financials — average growth

PAST 75/100

strong — trend

HEALTH 100/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 52/100

Gross margin is + market cap

FUTURE 0/100

Analyst outlook — as buy

INCOME 85/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — BVNKF

BVNKF trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

BVNKF: +37.6%/yr revenue is, +176.8%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

BVNKF: 3 / 4 years profitable. mixed. Score = 3 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet BVNKF: Debt-to-Equity (D/E) ratio 0.01 (conservative), Current ratio is 4.22 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

BVNKF: Gross margin is 47.4% (-6.6 pp trend), $2B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 52/100. ≥ 70 = Pass.

View details →

No analyst coverage available for this stock.

BVNKF: Net profit margin is 22.3%. healthy (≥15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range20.71-37.6

Volume100

Avg Volume (30D)83

Market Cap$2.41B

Beta (1Y)1.00

Share Statistics

EPS (TTM)17.61

Shares Outstanding$78.03M

IPO Date2010-10-15

Employees1,645

CEOPaul John Chaplin

Financial Highlights & Ratios

Revenue (TTM)$6.16B

Gross Profit$2.92B

EBITDA$1.63B

Net Income$1.37B

Operating Income$918.69M

Total Cash$3.33B

Total Debt$130.57M

Net Debt$-1.58B

Total Assets$14.92B

Price / Earnings (P/E)1.7

Price / Sales (P/S)0.39

Analyst Forecast

Company Info

CountryDK

ExchangeOther OTC

CurrencyUSD

ISINDK0015998017

Price Chart

BVNKF

Bavarian Nordic A/S ↗ · Other OTC

Healthcare • Biotechnology

20.71 52WK RANGE 37.60

People Also View

United Therapeutics Corporation

Ascendis Pharma A/S

Edgewise Therapeutics, Inc.

Mineralys Therapeutics, Inc.

Ventyx Biosciences, Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message